echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In 2015, biopharmaceutical industry will become a pillar industry in China

    In 2015, biopharmaceutical industry will become a pillar industry in China

    • Last Update: 2011-07-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: it is estimated that by 2015, the output value of the biological industry will exceed 3 trillion yuan, which will become a new pillar industry in China Biomedicine, biomaterials, bioenergy and bio agriculture have become the priority areas of national development, which is promising According to Wang Changlin, Secretary General of the national biological industry development expert advisory committee, by 2015, the output value of China's biological industry will exceed 3 trillion yuan, and reach about 6 trillion yuan by 2020, surpassing the current scale of China's electronic information product manufacturing industry and becoming a new pillar industry in China Today, the world's major countries are making great efforts in the biological industry If China can speed up the pace of technological innovation and focus on promoting the effective industrialization of innovation achievements, it can conquer the peak of this era of biological economy 2009 6 In June, the state issued several policies for accelerating the development of biological industry, which clearly put forward the policy objectives of promoting the innovation and industrialization of biological technology and accelerating the scale, agglomeration and international development of biological industry Among them, biomedicine, biomaterials, bioenergy and biological agriculture have become the priority areas for development Our reporter interviewed the petrochemical and light textile business department of China consultative corporation Yi Jingwei, director of the chemical industry department, Guo Chen, director of the cooperative business department, Changle Youhua, director of the agriculture and Forestry Department of the agriculture, forestry and water business department and Dong Yiman, director of the agriculture and Forestry Department of the light industry department, interpret the above four key development areas Vaccine chip supporting vaccine development in biomedical industry has become the focus of the world How is the development of vaccine industry in China? What are the bottlenecks? What are the Countermeasures for the golden period of vaccine industry development in the world? China is a developing country with a large population, and its national economy is in the stage of rapid development However, the number of pathogen infections and infectious diseases in China ranks first in the world Various infectious diseases are repeatedly prevalent, and new infectious diseases are constantly emerging, which seriously harm people's health level and impact social order It has become one of the serious factors restricting the harmonious development of society and economic development Therefore, China needs to increase investment in vaccine research and development, enrich vaccine varieties, update vaccine research and development technology, accelerate the research speed of key technologies related to vaccines, provide effective and safe vaccines for the people, and make contributions to the development of a harmonious society At present, there are 38 vaccine manufacturers in China, which can produce 44 vaccines to prevent 26 infectious diseases Compared with the international market, the number of vaccine manufacturers in China is relatively large and the scale is small The international vaccine production is mainly supplied by developed countries in Europe and the United States, forming a pattern of competition among the top five companies, namely, Sanofi Pasteur (ASP), Pfizer (Wyeth), Merck, GSK and Novartis Due to the influence of economic and other technical factors, China's vaccine manufacturers are still in a relatively backward situation, in addition to their comparative advantages in individual varieties The vaccines produced in China are mainly imitated and absorbed by imported technology The main reason for the backward technology of vaccine manufacturing enterprises in China is that China has not mastered the key technologies, including cell scale culture technology and vaccine adjuvant with independent intellectual property rights Although the scale of genetic engineering development technology is still in a relatively backward position, the ability of technology transformation to industry is also a weak link In the future, China's vaccine industry will take the infectious diseases which are urgent, multiple and new and have great harm to human beings as the research goal of vaccine varieties, and provide vaccine technology and variety reserve in the form of building industrialization and technology platform; carry out the research of human zoonosis vaccine and strengthen the technical reserve; scale up the new cell matrix and culture technology and update the traditional vaccine Combine organically, develop new cell matrix and large-scale culture technology of mammalian cells; carry out post vaccination epidemiological and molecular epidemiological investigation of existing infectious disease vaccines, and do basic work for dealing with new infectious diseases; select several infectious diseases with great harm, strong infectivity and wide epidemic scope, and carry out strict epidemiological investigation, so as to make full use of Chinese personnel The advantages of large number of patients provide support for the research and development of vaccines with independent intellectual property rights; select several infectious diseases that must be developed by means of modern genetic engineering technology, strengthen the research and development of genetic engineering carriers with independent intellectual property rights, and improve the core competitiveness of vaccine enterprises in China; develop new types of vaccines Adjuvant and mucosal immune delivery technology are the main ways to provide basic guarantee for the development of new vaccines What is the current situation of biochip industrialization in China? What is the investment scale of biochip industry in China? Biochip research in China began in 1997-1998 Since 2000, China has invested nearly 500 million yuan in succession and established two national engineering research centers for biochips, Beijing and Shanghai, which laid a solid foundation for strengthening China's independent innovation and industrialization capacity in this emerging high-tech field During the Tenth Five Year Plan period, the National 863 Program focused on organizing and implementing the major project of "functional genomics and biochip research", which provided slanting support for the research and development of biochip system At present, the biochip industry has begun to take shape in China, with Beijing and Shanghai as the leading national engineering research centers, nearly 50 biochip R & D institutions and more than 30 biochip enterprises in Tianjin, Xi'an, Nanjing, Shenzhen, Harbin and other places developing vigorously Beijing Boao, Shanghai Biochip, Tianjin biochip and other enterprises have become the leading force of China's biochip industry China's biochip has achieved a number of research results, published nearly 20 papers in PNAS and other international authoritative journals, and declared 753 new gene clusters and marker gene clusters related to infectious diseases and tumors with independent intellectual property rights Since 2000, China's biochip has obtained more than 20 national new drug certificates and medical device certificates; applied for more than 400 domestic patents and more than 100 foreign patents; at the same time, there are nearly 400 biochips and related products, involving gene, protein, cell and tissue.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.